Latest NSCLC Stories
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma provides information on pricing, market analysis, shares, forecast, and company
LUGANO, Switzerland, October 30, 2014 /PRNewswire/ -- In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue
Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct.
- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical
New research report “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market” elaborated by GBI Research
- To give a box on the ear to.